Randomized trial · people
MK-677 raised bone turnover markers in adults 65 and older
Checked against the paper Randomized trialPublished by PepVault
The takeaway
MK-677 sped up markers of both bone breakdown and bone building in older adults over a few weeks, but this paper does not show whether bones got stronger.
- Kind
- Randomized trial
- Studied in
- People
- Number studied
- 187
- Published
- 1999
- Journal
- J Bone Miner Res
What they tested
The team tested whether taking MK-677 by mouth every day changes IGF-I, a growth-related hormone in the blood, and markers of bone turnover in older adults.
How the study was done
A set of randomized, double-blind, placebo-controlled trials (placebo, a dummy pill) in 187 adults aged 65 or older, lasting 2 to 9 weeks. The earlier trials enrolled healthy older adults, and the last one enrolled 105 older adults who met set criteria for functional impairment.

What they found
In healthy older adults, 2 weeks in the 10 mg and 25 mg arms raised urine NTX, a marker of bone breakdown, by 10% and 17% compared with placebo. In another healthy group given 25 mg and then 50 mg, serum osteocalcin, a marker of bone building, rose by 8%, and IGF-I rose by 55-94% across these healthy-adult trials. In functionally impaired adults treated for 9 weeks, osteocalcin rose 29.4%, BSAP (bone-specific alkaline phosphatase, another bone-building marker) rose 10.4%, and urine NTX rose 22.6% versus placebo. The rise in osteocalcin tracked with the rise in IGF-I (r = 0.37).
What it doesn’t show
These were short trials of 2 to 9 weeks with small groups, and they measured only blood and urine markers. They did not test bone density, bone strength or fractures.
The paper
Murphy et al. Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults. The MK-677 Study Group. J Bone Miner Res. 1999.
The compound
More studies on MK-677
- MK-677 raised IGF-1 but not most function after hip fractureRandomized trial · people · 2011
- MK-677: fat-free mass rose 1.1 kg vs -0.5 kg on placebo at 1 yearRandomized trial · people · 2008
- MK-677 plus alendronate: 4.2% femoral neck BMD gain vs 2.5% aloneRandomized trial · people · 2001
- MK-677 reversed diet-driven nitrogen loss in 8 healthy adultsRandomized trial · people · 1998
- MK-677: IGF-I rose 52% at 10 mg and 79% at 50 mg in GH-deficient menRandomized trial · people · 1997
- MK-677: moderate GH isoform shifts over 8 weeks in obese menClinical trial · people · 2003
- Every study on MK-677
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.